Dr. Vokes on Biomarker Selection in Head and Neck Cancer
March 22nd 2017Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses biomarkers for immunotherapy in head and neck cancer.
Dr. Luke on Adjuvant Therapies in Development for Melanoma
March 20th 2017Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses some of the ongoing adjuvant therapies in development for patients with melanoma. Luke shared this insight during the 2017 OncLive State of the Science Summit on Melanoma and Immuno-Oncology.
Dr. Levine on Palliative Care for NSCLC
March 7th 2017Stacie Levine, MD, associate professor of Medicine, director, Geriatrics and Hospice and Palliative Medicine Fellowship Program, University of Chicago Medicine, discusses the benefits of palliative care for patients with non–small cell lung cancer (NSCLC).
Dr. Vokes on Different Settings in Head and Neck Cancer
February 16th 2017Everett Vokes, MD, John E. Ultmann professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses different settings of patients with head and neck cancer.
Dr. Levine on Simulation in the Management of EGFR-Mutated Advanced NSCLC
February 11th 2017Stacie Levine, MD, associate professor of Medicine, Director, Geriatrics and Hospice and Palliative Medicine Fellowship Program, The University of Chicago Medicine, discusses a trial regarding simulation in the management of EGFR-mutated advanced NSCLC
Dr. Vokes on Recent Progress in the Treatment Landscape of Head and Neck Cancer
January 19th 2017Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses recent progress in the treatment landscape of head and neck cancer.
Dr. Vokes on Moving Immunotherapy into Frontline for Head and Neck Cancer
January 6th 2017Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses the possibility of moving immunotherapy agents into the frontline setting for patients with head and neck cancer.
Dr. Vokes on Selecting Nivolumab or Pembrolizumab for Head and Neck Cancer Treatment
December 28th 2016Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses how to choose between nivolumab (Opdivo) and pembrolizumab (Keytruda) for second-line treatment for patients with head and neck cancer.
Dr. Seiwert on Prognosis for Patients With Head and Neck Cancer
December 23rd 2016Tanguy Y. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the current prognosis for patients with head and neck cancer prior to the FDA approvals of immunotherapy agents nivolumab (Opdivo) and pembrolizumab (Keytruda) as treatments.
Dr. Vokes on Curative Treatment Approaches in Head and Neck Cancer
December 2nd 2016Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses curative treatment approaches for patients with head and neck cancer.
IDO Inhibitors Among Immunotherapy Strategies Under Study in Glioblastoma
November 30th 2016The concept of using immunotherapies to treat patients with glioblastoma multiforme is gaining ground among researchers who are interested not only in evaluating checkpoint blockade agents that have proved effective in other tumor types but also in exploring novel targets.
Dr. Zagaja on Major Benefit With Prostatectomy
November 1st 2016Gregory Zagaja, MD, professor of Surgery, director of the Prostate Cancer Center at the University of Chicago Medicine, discusses the benefits of radical prostatectomy for patients with prostate cancer. Zagaja shared this insight during an interview at the 2016 OncLive State of the Science Summit on GU and Prostate Cancer.
Dr. Eggener on PSA-Based Screening in Early-Stage Prostate Cancer
October 31st 2016Scott Eggener, MD, associate professor of Surgery, Urologic Oncology, at the University of Chicago Medicine, discusses his views on PSA-based screening and how to appropriately use it for patients with early-stage prostate cancer. Eggier shared these thoughts during the 2016 OncLive State of the Science Summit on GU and Prostate Cancer.